The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Predictors of early discontinuation of chemotherapy (EDC) in patients (pts) age 65 or older with stage IV non-small cell lung cancer (NSCLC).
Ajeet Gajra
No relevant relationships to disclose
William P. Tew
No relevant relationships to disclose
Molly Hardt
No relevant relationships to disclose
Supriya Gupta Mohile
No relevant relationships to disclose
Cynthia Owusu
No relevant relationships to disclose
Heidi D. Klepin
No relevant relationships to disclose
Cary P. Gross
No relevant relationships to disclose
Stuart M. Lichtman
No relevant relationships to disclose
Vani Katheria
No relevant relationships to disclose
Arti Hurria
Consultant or Advisory Role - Amgen; Genentech; GTx
Research Funding - Abraxis BioScience; Celgene; GlaxoSmithKline